Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

SEL24 / MEN1703 in Patients With Acute Myeloid Leukemia


The purpose of the clinical trial is to identify the highest dose of SEL24 / MEN1703 drug with acceptable safety profile and that can be used in patients with Acute Myeloid Leukemia.
Strickland, Stephen

A Study of ME-401 in Subjects With CLL / SLL, FL, and B-cell Non-Hodgkin's Lymphoma

Multiple Cancer Types

This is a two-arm, Phase 1b, open-label, dose escalation study of ME-401 alone and an open-label study of ME-401 in combination with rituximab in patients with relapsed / refractory B-cell malignancies.
Leukemia, Lymphoma
Reddy, Nishitha

Nivolumab and Ipilimumab in Estimating Anti-Tumor Activity and Identifying Potential Predictors of Response in Patients with Melanoma That is Metastatic or Cannot Be Removed by Surgery


This phase II trial studies how well nivolumab and ipilimumab work in estimating anti-tumor activity and identifying potential predictors of response in patients with melanoma that is spreading to other places in the body or that cannot be removed by surgery. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.
Johnson, Douglas

Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1)

Multiple Cancer Types

GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonist antibody intended for the treatment of cancers of different histology. This is a first-time-in-human (FTIH), open-label, multicenter study designed to investigate the safety, pharmacology, and preliminary antitumor activity in subjects with advanced or recurrent solid tumors with the aim to establish recommended dose(s) of GSK3359609 for further exploration as monotherapy and in combination with pembrolizumab or chemotherapy regimens. The study is comprised of two primary parts, each composed of two phases: Part 1: GSK3359609 monotherapy with Part 1A as dose escalation phase and Part 1B as cohort expansion phase; Part 2: GSK3359609 combination therapy with Part 2A pembrolizumab or GSK3174998 combination dose escalation phase and Part 2B expansion phase with pembrolizumab. Part 2A GSK3359609 combinations with chemotherapy will only consist of safety run-in cohorts. Each part and phase of the study includes a screening period, a treatment period, and a follow-up period. The primary objective of the study is to determine the safety, tolerability, maximum tolerated dose or the maximum administered dose of GSK3359609 alone or in combination.
Lung, Non Small Cell, Phase I
Horn, Leora

MRI in Measuring Tumor Growth and Treatment Response in Patients with Breast Tumors and Healthy Volunteers

This clinical trial studies magnetic resonance imaging (MRI) in measuring tumor growth and treatment response in patients with breast tumors and healthy volunteers. Diagnostic procedures, such as dynamic contrast enhanced MRI (DCE-MRI), diffusion weighted MRI (DW-MRI), and magnetic resonance spectroscopy (MRS), may help characterize breast tumors to develop potential surrogate imaging markers for diagnosis and treatment response.
Not Available
Chak, Bapsi

Neuropsychological and Behavioral Testing in Younger Patients with Cancer

Multiple Cancer Types

This research trial studies neuropsychological (learning, remembering or thinking) and behavioral testing in younger patients with cancer. Collecting information over time from a series of tests may help doctors develop effective tests to measure neuropsychological and behavioral function of patients with cancer.
Miscellaneous, Neuro-Oncology, Pediatrics
Friedman, Debra

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies


This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.
Friedman, Debra

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)


This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
Kassim, Adetola

Collection of Tissue Samples for Cancer Research

Multiple Cancer Types

Background: -Patients who are being evaluated and / or treated at the NIH Clinical Center (pediatric and adult) and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens. Objectives: - To obtain samples from adult and pediatric patients for research purposes from tests and procedures that are done as required by the primary research protocol(s) to which a patient is enrolled or as part of their standard-of-care treatment. - To obtain samples for research purposes from non-surgical procedures, such as percutaneous biopsies, performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol. Eligibility: -Adult patients (18 years of age and older) and pediatric patients (younger than 18 years of age) who are being evaluated for and / or treated for cancer at the NIH Clinical Center and adult patients from participating sites. Design: - This is a multicenter tissue procurement protocol with NCI as the coordinating center. - For adult patients: specimens for research purposes, as outlined in this protocol, will be obtained from tests and procedures that are done as required by the primary research protocols to which a patient is enrolled or as part of their standard-of-care treatment. Non-surgical procedures, such as percutaneous biopsies, may also be performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol. Tissues and biological fluids to be procured may include but are not limited to blood, serum, urine, tumor tissue, normal tissue, pleural fluid, CSF, saliva, bronchial alveolar lavage (BAL), circulating tumor cells, hair follicles, and bone marrow. These specimens will be stored with unique identifiers and used to perform only those research studies that are outlined in this protocol. - For pediatric patients: tumor biopsy / resection tissue used for pediatric preclinical model development will only be from tissue already being obtained as part of a procedure necessary for the patient s clinical care or as part of a primary research protocol; blood specimens will be collected as part of a blood collection already scheduled for the patient s clinical care or as part of the planned pre-procedure bloodwork; volumes collected will not exceed institutional research limits. - Given the risks associated with any invasive procedure, such as tumor biopsy, the procedure will be discussed in detail with the patients and their parents / guardian (as indicated), including the side effects, prior to obtaining a separate consent for each procedure. A separate consent will not be signed prior to obtaining samples by minimally invasive measures, such as venipuncture. - This study has three separate consent forms: one for adult patients at the NIH Clinical Center to opt to donate their samples for ongoing research on assay development and studies of molecular pathways; and two for the generation of preclinical models (adult and pediatric). Adult patients at the NIH and participating sites, and also pediatric patients (NIH Clinical Center only), can opt to donate samples to create preclinical models to study tumor biology and genetics, and to develop new therapies for cancer. - Patients may remain on study for the duration of their consent or completion of the planned procedure, whichever comes first.
Lung, Miscellaneous, Small Cell
Pietenpol, Jennifer

11C-Glutamine and 18F-FSPG PET Imaging in Diagnosing Patients with Metastatic Colorectal Cancer

Multiple Cancer Types

The clinical trial studies how well 11C-glutamine and 18F-FSPG positron emission tomography (PET) imaging works in detecting tumors in patients with metastatic colorectal cancer compared to standard imaging methods such as magnetic resonance imaging (MRI) or computed tomography (CT) scanning.
Colon, Rectal
Manning, Henry

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: